Selected article for: "distress syndrome and SARS effect"

Author: Hernández-Mora, Miguel Górgolas; Cabello Úbeda, Alfonso; Pérez, Laura Prieto; Álvarez, Felipe Villar; Álvarez, Beatriz Álvarez; Rodríguez Nieto, María Jesús; Acosta, Irene Carrillo; Ormaechea, Itziar Fernández; Al-Hayani, Aws Waleed Mohammed; Carballosa, Pilar; Martínez, Silvia Calpena; Ezzine, Farah; González, Marina Castellanos; Naya, Alba; de las Heras, Marta López; Rodríguez Guzmán, Marcel José; Guijarro, Ana Cordero; Lavado, Antonio Broncano; Valcayo, Alicia Macías; García, Marta Martín; Martínez, Javier Bécares; Roblas, Ricardo Fernández; Piris Pinilla, Miguel Ángel; Alen, José Fortes; Pernaute, Olga Sánchez; Bueno, Fredeswinda Romero; Frades, Sarah Heili; Romero, Germán Peces Barba
Title: Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia
  • Cord-id: 5mrkmctl
  • Document date: 2020_10_25
  • ID: 5mrkmctl
    Snippet: INTRODUCTION: Tocilizumab is an interleukin 6 receptor antagonist which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), aiming to ameliorate the cytokine release syndrome (CRS) -induced acute respiratory distress syndrome (ARDS). However, there are no consistent data whom might benefit most from it. METHODS: We provided tocilizumab on a compassionate-use basis to patients with SSP hospitalized (excluding intensive care and intubated cases) who required oxygen support to hav
    Document: INTRODUCTION: Tocilizumab is an interleukin 6 receptor antagonist which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), aiming to ameliorate the cytokine release syndrome (CRS) -induced acute respiratory distress syndrome (ARDS). However, there are no consistent data whom might benefit most from it. METHODS: We provided tocilizumab on a compassionate-use basis to patients with SSP hospitalized (excluding intensive care and intubated cases) who required oxygen support to have a saturation >93%. Primary endpoint was intubation or death after 24 hours of its administration. Patients received at least one dose of 400 mg intravenous tocilizumab during March 8-2020, through April 20-2020. RESULTS: A total of 207 patients were studied and 186 analysed. The mean age was 65 years and 68% were male. A co-existing condition was present in 68 % of cases. Death prognostic factors were older age, higher IL-6, D-dimer and high sensitivity C reactive protein (HSCRP), lower total lymphocytes and severe disease requiring higher oxygen support. The primary endpoint (intubation or death) was significantly worst (37% vs 13%, p < 0·001) in those receiving the drug when the oxygen support was high (FiO2 > 0.5%). CONCLUSIONS: Tocilizumab is well tolerated in patients with severe SARS-CoV-2 pneumonia, but it has a limited effect on the evolution of cases with high oxygen support needs.

    Search related documents:
    Co phrase search for related documents